Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01482962




Registration number
NCT01482962
Ethics application status
Date submitted
28/11/2011
Date registered
1/12/2011
Date last updated
31/07/2018

Titles & IDs
Public title
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Scientific title
A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Secondary ID [1] 0 0
2011-003545-18
Secondary ID [2] 0 0
C14012
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Relapsed Peripheral T-Cell Lymphoma 0 0
Refractory Peripheral T-Cell Lymphoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Alisertib
Treatment: Drugs - Pralatrexate
Treatment: Drugs - Gemcitabine
Treatment: Drugs - Romidepsin

Experimental: Alisertib - Alisertib 50 mg, enteric-coated tablet formulation, orally, twice daily for 7 consecutive days (Cycle Days 1-7) in a 21-day cycle (Up to 148 Weeks).

Active comparator: Pralatrexate, or Romidepsin, or Gemcitabine - Pralatrexate 30 mg/m\^2, intravenous (IV) push over 3 to 5 minutes, once weekly, for 6 weeks in 7-week cycles with concurrent vitamin B12 and folic acid supplementation. Cycles were repeated every 7-weeks provided the participant continued to benefit from and tolerate the therapy (Up to 115 Weeks), or Gemcitabine 1,000 mg/m\^2 over 30 minutes, intravenously, on Days 1, 8, and 15 of a 28-day cycle until the absence of disease progression or unacceptable toxicity (Up to 32 Weeks), or Romidepsin 14 mg/m\^2, intravenously over a 4-hour period, on Days 1, 8, and 15 of a 28-cycle. Cycles were repeated every 28 days provided the patient continued to benefit from and tolerate the therapy (Up to 30 Weeks).


Treatment: Drugs: Alisertib
Alisertib enteric coated tablets

Treatment: Drugs: Pralatrexate
Pralatrexate IV infusion

Treatment: Drugs: Gemcitabine
Gemcitabine IV infusion

Treatment: Drugs: Romidepsin
Romidepsin IV infusion
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment
Timepoint [1] 0 0
Every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until progressive disease. Duration is approximately 3 years
Primary outcome [2] 0 0
Progression-Free Survival (PFS) Based on IRC Assessment
Timepoint [2] 0 0
Every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until progressive disease. Duration is approximately 3 years
Secondary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
Participants were followed for survival for 2 years from date of last participant off study treatment, or death, whichever occurs first. Contacts were every 4 months (Median follow-up 519 days in the alisertib arm and 586 days in the comparative arm)
Secondary outcome [2] 0 0
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Timepoint [2] 0 0
First dose to 30 days after last dose of study drug or comparator (Up to 152 Weeks)
Secondary outcome [3] 0 0
Number of Participants With Clinically Important Abnormal Laboratory Values Reported as AEs
Timepoint [3] 0 0
First dose to 30 days after last dose of study drug or comparator (Up to 152 Weeks)
Secondary outcome [4] 0 0
Number of Participants With Clinically Important Vital Sign Measurements Reported as AEs
Timepoint [4] 0 0
First dose to 30 days after last dose of study drug or comparator (Up to 152 Weeks)
Secondary outcome [5] 0 0
Complete Response (CR) Rate
Timepoint [5] 0 0
At the end of every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until PD (approximately 3 years)
Secondary outcome [6] 0 0
Time to Disease Progression (TTP)
Timepoint [6] 0 0
At the end of every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until progressive disease. Duration is approximately 3 years
Secondary outcome [7] 0 0
Duration of Response (DOR)
Timepoint [7] 0 0
At the end of every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until progressive disease. Duration is approximately 3 years
Secondary outcome [8] 0 0
Time to Response
Timepoint [8] 0 0
At the end of every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until progressive disease. Duration is approximately 3 years
Secondary outcome [9] 0 0
Time to Subsequent Antineoplastic Therapy
Timepoint [9] 0 0
From date of last study drug to date of subsequent antineoplastic therapy, if required; approximately 3 years
Secondary outcome [10] 0 0
Plasma Concentration-time Data to Contribute to Future Population Pharmacokinetics (PK) Analysis
Timepoint [10] 0 0
Cycle 1, Days 1 and 7; Cycle 2, Day 8; Cycle 3, Day 8; Cycle 4, Day 8. Duration is approximately 4 months.
Secondary outcome [11] 0 0
Change Form Baseline in Reported Symptoms and Quality of Life (QoL) Assessment Per Functional Assessment of Cancer Therapy-Lymphoma (FACT-LYM) for Functioning and Symptoms
Timepoint [11] 0 0
Baseline and End of Treatment (EOT) (Up to 152 Weeks)

Eligibility
Key inclusion criteria
* Male or female participants age 18 or older
* Participants with Peripheral T cell lymphoma (PTCL) (selected subtypes) according to World Health Organization (WHO) criteria and have relapsed or are refractory to at least 1 prior systemic, cytotoxic therapy for PTCL. Participants must have received conventional therapy as a prior therapy. Cutaneous-only disease is not permitted. Participants must have documented evidence of progressive and measurable disease.
* Tumor biopsy available for central hematopathologic review
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
* Female participants who are post menopausal for at least 1 year, surgically sterile, or agree to practice 2 effective methods of contraception through 30 days after the last dose of study drug or agree to abstain from heterosexual intercourse.
* Male participants who agree to practice effective barrier contraception through 6 months after the last dose of alisertib or agree to abstain from heterosexual intercourse
* Suitable venous access
* Voluntary written consent
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

* Known central nervous system lymphoma
* Systemic antineoplastic therapy, immunotherapy, investigational agent or radiation therapy within 4 weeks of first dose of study treatment or concomitant use during study
* Prior administration of an Aurora A kinase-targeted agent, including alisertib; or all of the 3 comparator drugs (pralatrexate, or romidepsin or gemcitabine; or known hypersensitivity)
* History of uncontrolled sleep apnea syndrome or other conditions that could result in excessive daytime sleepiness
* Cardiac condition as specified in study protocol, including left ventricular ejection fraction (LVEF) <40%
* Concomitant use of other medicines as specified in study protocol
* Participants with abnormal gastric or bowel function who require continuous treatment with H2-receptor antagonists or proton pump inhibitors
* Known active infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C
* Autologous stem cell transplant less than 3 months prior to enrollment
* Participants who have undergone allogeneic stem cell or organ transplantation any time
* Inadequate blood levels, bone marrow or other organ function as specified in study protocol
* The participant must have recovered to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade = 1 toxicity, to participant's baseline status (except alopecia), or deemed irreversible from the effects of prior cancer therapy
* Major surgery, serious infection, or infection requiring systemic antibiotic therapy within 14 days prior to the first dose of study treatment
* Female participants who are breastfeeding or pregnant
* Coexistent second malignancy or history of prior solid organ malignancy within previous 3 years
* Serious medical or psychiatric illness or laboratory abnormality that could, in the investigator's opinion, potentially interfere with the completion of treatment according to the protocol

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
11/06/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
18/12/2017
Sample size
Target
Accrual to date
Final
271
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Adelaide
Recruitment hospital [2] 0 0
- Concord
Recruitment hospital [3] 0 0
- Gosford
Recruitment hospital [4] 0 0
- Hobart
Recruitment hospital [5] 0 0
- St Leonards
Recruitment postcode(s) [1] 0 0
- Adelaide
Recruitment postcode(s) [2] 0 0
- Concord
Recruitment postcode(s) [3] 0 0
- Gosford
Recruitment postcode(s) [4] 0 0
- Hobart
Recruitment postcode(s) [5] 0 0
- St Leonards
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Indiana
Country [5] 0 0
United States of America
State/province [5] 0 0
Iowa
Country [6] 0 0
United States of America
State/province [6] 0 0
Massachusetts
Country [7] 0 0
United States of America
State/province [7] 0 0
Michigan
Country [8] 0 0
United States of America
State/province [8] 0 0
Minnesota
Country [9] 0 0
United States of America
State/province [9] 0 0
Missouri
Country [10] 0 0
United States of America
State/province [10] 0 0
New Hampshire
Country [11] 0 0
United States of America
State/province [11] 0 0
New Jersey
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
North Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Ohio
Country [15] 0 0
United States of America
State/province [15] 0 0
South Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Texas
Country [17] 0 0
United States of America
State/province [17] 0 0
Vermont
Country [18] 0 0
United States of America
State/province [18] 0 0
Washington
Country [19] 0 0
United States of America
State/province [19] 0 0
West Virginia
Country [20] 0 0
Austria
State/province [20] 0 0
Graz
Country [21] 0 0
Austria
State/province [21] 0 0
Innsbruck
Country [22] 0 0
Austria
State/province [22] 0 0
Salzburg
Country [23] 0 0
Austria
State/province [23] 0 0
Wien
Country [24] 0 0
Belarus
State/province [24] 0 0
Minsk Didtrict
Country [25] 0 0
Belarus
State/province [25] 0 0
Vitebsk
Country [26] 0 0
Belgium
State/province [26] 0 0
Brugge
Country [27] 0 0
Belgium
State/province [27] 0 0
Brussels
Country [28] 0 0
Belgium
State/province [28] 0 0
Gent
Country [29] 0 0
Belgium
State/province [29] 0 0
Kortrijk
Country [30] 0 0
Belgium
State/province [30] 0 0
Turnhout
Country [31] 0 0
Belgium
State/province [31] 0 0
Yvoir
Country [32] 0 0
Brazil
State/province [32] 0 0
Belo Horizonte
Country [33] 0 0
Brazil
State/province [33] 0 0
Campianas
Country [34] 0 0
Brazil
State/province [34] 0 0
Caxias Do Sul
Country [35] 0 0
Brazil
State/province [35] 0 0
Curitiba
Country [36] 0 0
Brazil
State/province [36] 0 0
Goiania
Country [37] 0 0
Brazil
State/province [37] 0 0
Porto Alegre/rs
Country [38] 0 0
Brazil
State/province [38] 0 0
Porto Alegre
Country [39] 0 0
Brazil
State/province [39] 0 0
Rio de Janeiro
Country [40] 0 0
Brazil
State/province [40] 0 0
Salvador
Country [41] 0 0
Brazil
State/province [41] 0 0
SAO Paulo - SP
Country [42] 0 0
Brazil
State/province [42] 0 0
Sao Paulo
Country [43] 0 0
Bulgaria
State/province [43] 0 0
Pleven
Country [44] 0 0
Bulgaria
State/province [44] 0 0
Sofia
Country [45] 0 0
Bulgaria
State/province [45] 0 0
Varna
Country [46] 0 0
Canada
State/province [46] 0 0
Ontario
Country [47] 0 0
Chile
State/province [47] 0 0
Concepcion
Country [48] 0 0
Chile
State/province [48] 0 0
Santiago
Country [49] 0 0
Czechia
State/province [49] 0 0
Praha 2
Country [50] 0 0
Denmark
State/province [50] 0 0
Arhus C
Country [51] 0 0
Denmark
State/province [51] 0 0
Kobenhavn O
Country [52] 0 0
Egypt
State/province [52] 0 0
Alexandria
Country [53] 0 0
Egypt
State/province [53] 0 0
Beni Swef
Country [54] 0 0
Egypt
State/province [54] 0 0
Cairo
Country [55] 0 0
Egypt
State/province [55] 0 0
Dakahlia
Country [56] 0 0
France
State/province [56] 0 0
Bordeaux
Country [57] 0 0
France
State/province [57] 0 0
Marseille
Country [58] 0 0
France
State/province [58] 0 0
Paris
Country [59] 0 0
France
State/province [59] 0 0
Pessac
Country [60] 0 0
France
State/province [60] 0 0
Pierre Benite
Country [61] 0 0
France
State/province [61] 0 0
Tours
Country [62] 0 0
Germany
State/province [62] 0 0
Berlin
Country [63] 0 0
Germany
State/province [63] 0 0
Essen
Country [64] 0 0
Germany
State/province [64] 0 0
Freiburg
Country [65] 0 0
Germany
State/province [65] 0 0
Goettingen
Country [66] 0 0
Germany
State/province [66] 0 0
Homburg/saar
Country [67] 0 0
Germany
State/province [67] 0 0
Mainz
Country [68] 0 0
Germany
State/province [68] 0 0
Muenchen
Country [69] 0 0
Germany
State/province [69] 0 0
Munchen
Country [70] 0 0
Germany
State/province [70] 0 0
ULM
Country [71] 0 0
Hungary
State/province [71] 0 0
Budapest
Country [72] 0 0
Hungary
State/province [72] 0 0
Debrecen
Country [73] 0 0
Hungary
State/province [73] 0 0
Kaposvar
Country [74] 0 0
Hungary
State/province [74] 0 0
Pecs
Country [75] 0 0
Israel
State/province [75] 0 0
Beer-sheva
Country [76] 0 0
Israel
State/province [76] 0 0
Haifa
Country [77] 0 0
Israel
State/province [77] 0 0
Jerusalem
Country [78] 0 0
Israel
State/province [78] 0 0
Petach Tikva
Country [79] 0 0
Israel
State/province [79] 0 0
Ramat-gan
Country [80] 0 0
Israel
State/province [80] 0 0
Tel Aviv
Country [81] 0 0
Italy
State/province [81] 0 0
Bari
Country [82] 0 0
Italy
State/province [82] 0 0
Bologna
Country [83] 0 0
Italy
State/province [83] 0 0
Cagliari
Country [84] 0 0
Italy
State/province [84] 0 0
Firenze
Country [85] 0 0
Italy
State/province [85] 0 0
Meldola
Country [86] 0 0
Italy
State/province [86] 0 0
Modena
Country [87] 0 0
Italy
State/province [87] 0 0
Ravenna
Country [88] 0 0
Italy
State/province [88] 0 0
Rimini
Country [89] 0 0
Italy
State/province [89] 0 0
Roma
Country [90] 0 0
Italy
State/province [90] 0 0
Torino
Country [91] 0 0
Mexico
State/province [91] 0 0
Durango Durango
Country [92] 0 0
Mexico
State/province [92] 0 0
Mexico
Country [93] 0 0
Mexico
State/province [93] 0 0
Monterrey Nuevo LEON
Country [94] 0 0
Mexico
State/province [94] 0 0
Monterrey
Country [95] 0 0
Mexico
State/province [95] 0 0
San Luis Potosi
Country [96] 0 0
Netherlands
State/province [96] 0 0
Maastricht
Country [97] 0 0
Netherlands
State/province [97] 0 0
Nieuwegein
Country [98] 0 0
New Zealand
State/province [98] 0 0
Auckland
Country [99] 0 0
New Zealand
State/province [99] 0 0
Christchurch
Country [100] 0 0
New Zealand
State/province [100] 0 0
Takapuna
Country [101] 0 0
Peru
State/province [101] 0 0
Arequipa
Country [102] 0 0
Peru
State/province [102] 0 0
Lima
Country [103] 0 0
Poland
State/province [103] 0 0
Bydgoszcz
Country [104] 0 0
Poland
State/province [104] 0 0
Chorzow
Country [105] 0 0
Poland
State/province [105] 0 0
Krakow
Country [106] 0 0
Poland
State/province [106] 0 0
Lodz
Country [107] 0 0
Poland
State/province [107] 0 0
Warszawa
Country [108] 0 0
Poland
State/province [108] 0 0
Wroclaw
Country [109] 0 0
Portugal
State/province [109] 0 0
Braga
Country [110] 0 0
Portugal
State/province [110] 0 0
Coimbra
Country [111] 0 0
Portugal
State/province [111] 0 0
Porto
Country [112] 0 0
Puerto Rico
State/province [112] 0 0
San Juan
Country [113] 0 0
Romania
State/province [113] 0 0
Bucuresti
Country [114] 0 0
Russian Federation
State/province [114] 0 0
Chelyabinsk
Country [115] 0 0
Russian Federation
State/province [115] 0 0
Moscow
Country [116] 0 0
Russian Federation
State/province [116] 0 0
Petrozavodsk
Country [117] 0 0
Russian Federation
State/province [117] 0 0
St Petersburg
Country [118] 0 0
Slovakia
State/province [118] 0 0
Bratislava
Country [119] 0 0
Slovakia
State/province [119] 0 0
Martin
Country [120] 0 0
Spain
State/province [120] 0 0
Barcelona
Country [121] 0 0
Spain
State/province [121] 0 0
Girona
Country [122] 0 0
Spain
State/province [122] 0 0
Madrid
Country [123] 0 0
Spain
State/province [123] 0 0
Pamplona
Country [124] 0 0
Spain
State/province [124] 0 0
Salamanca
Country [125] 0 0
Spain
State/province [125] 0 0
Sevilla
Country [126] 0 0
Spain
State/province [126] 0 0
Valencia
Country [127] 0 0
Sweden
State/province [127] 0 0
Linkoping
Country [128] 0 0
Sweden
State/province [128] 0 0
Lund
Country [129] 0 0
Sweden
State/province [129] 0 0
Solna
Country [130] 0 0
Turkey
State/province [130] 0 0
Ankara
Country [131] 0 0
Turkey
State/province [131] 0 0
Denizli
Country [132] 0 0
Turkey
State/province [132] 0 0
Istanbul
Country [133] 0 0
Turkey
State/province [133] 0 0
Kayseri
Country [134] 0 0
Turkey
State/province [134] 0 0
Samsun
Country [135] 0 0
United Kingdom
State/province [135] 0 0
Birmingham
Country [136] 0 0
United Kingdom
State/province [136] 0 0
Cardiff
Country [137] 0 0
United Kingdom
State/province [137] 0 0
Liverpool
Country [138] 0 0
United Kingdom
State/province [138] 0 0
Manchester
Country [139] 0 0
United Kingdom
State/province [139] 0 0
Newcastle Upon Tyne
Country [140] 0 0
United Kingdom
State/province [140] 0 0
Southampton
Country [141] 0 0
United Kingdom
State/province [141] 0 0
Truro

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Millennium Pharmaceuticals, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a phase 3, randomized, 2-arm, open-label, international trial evaluating alisertib compared with single-agent treatment, as selected by the investigator from the offered options of pralatrexate or gemcitabine or romidepsin, in participants with relapsed or refractory peripheral T-cell lymphoma (PTCL). Note: romidepsin was not used as a single-agent comparator outside the United States of America (USA) as supply was not available.
Trial website
https://clinicaltrials.gov/study/NCT01482962
Trial related presentations / publications
O'Connor OA, Ozcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, Beaven A, Caballero D, Horwitz SM, Lennard A, Turgut M, Hamerschlak N, d'Amore FA, Foss F, Kim WS, Leonard JP, Zinzani PL, Chiattone CS, Hsi ED, Trumper L, Liu H, Sheldon-Waniga E, Ullmann CD, Venkatakrishnan K, Leonard EJ, Shustov AR; Lumiere Study Investigators. Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. J Clin Oncol. 2019 Mar 10;37(8):613-623. doi: 10.1200/JCO.18.00899. Epub 2019 Feb 1.
Public notes

Contacts
Principal investigator
Name 0 0
Medical Monitor
Address 0 0
Takeda Oncology
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01482962